|Bid||6.70 x 1000|
|Ask||6.91 x 1000|
|Day's Range||6.61 - 7.01|
|52 Week Range||4.06 - 12.09|
|Beta (5Y Monthly)||1.70|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Has been selected to present four posters at the 2023 American Association for Cancer Research (AACR) ...
PHILADELPHIA and VANCOUVER, British Columbia, March 15, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, has been selected to present four posters at the 2023 American Association for Cancer Research (AACR) Annual Meeting held from April 14 - 19, 2023 at Orange County Convention Center, Orlando, Florida. The available abstract titles and
From what we can see, insiders were net buyers in BriaCell Therapeutics Corp.'s ( TSE:BCT ) during the past 12 months...